Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis

Gut

Volumn 40, Issue 5, 1997, Pages 623-627

  Hacker, U T ^a   Gomolka, M ^a   Keller, E ^a   Eigler, A ^a   Folwaczny, C ^a   Fricke, H ^a   Albert, E ^a   Loeschke, K ^a   Endres, S ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cytokine; Genetics; Inflammatory bowel disease; Interleukin 1 receptor antagonist; Polymorphism; Ulcerative colitis

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0030912691     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.5.623     Document Type: Article

References (36)

1. Satsangi J, Jewell DP, Rosenberg WM, Bell JI. Genetics of inflammatory bowel disease. Gut 1994; 35: 696-700.
2. Farmer RG, Michener WM, Mortimer EA. Studies of family history among patients with inflammatory bowel disease. Clin Gastroenterol 1980; 9: 271-7.
3. Yang H, McElree C, Roth MP, Shanahan F, Targan SR, Rotter JI. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993; 34: 517-24.
4. Yang H, Rotter JI, Toyoda H, Landers C, Tyran D, McElree CK, et al. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993; 92: 1080-4.
5. Roth MP, Petersen GM, McElree C, Vadheim CM, Panish JF, Rotter JI. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology 1989; 96: 1016-20.
6. Tysk C, Lindberg E, Jarnerot G, Floderus MB. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988; 29: 990-6.
7. Satsangi J, Welsh KI, Bunce M, Julier C, Farrant JM, Bell JI, et al. Contribution of genes of the mayor histocompatibility complex and disease phenotype in inflammatory bowel disease. Lancet 1996; 347: 1212-7.
8. Toyoda H, Wang SJ, Yang HY, Redford A, Magalong D, Tyan D, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993; 104: 741-8.
9. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
10. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994; 8: 1314-25.
11. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-52.
12. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336-40.
13. Carter DB, Deibel MJ, Dunn CJ, Tomich CS, Laborde AL, Slightom JL, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990; 344: 633-8.
14. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12: 404-10.
15. Eisenberg SP, Evans RJ, Arend WP, Verderber K, Brewer MT, Hannum CH, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341-6.
16. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88: 1445-51.
17. Eisenberg SP, Brewer MT, Verderber H, Heimdal P, Brandhuber BJ, Thompson RC. Interleukin 1 receptor antagonist is a member of the interleukin-1 gene family: evolution of a cytokine control mechanism. Proc Natl Acad Sci USA 1991; 88: 5232-6.
18. Casini RV, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995; 154: 2434-40.
19. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 403-4.
20. Mansfield JC, Holden H, Tarlow JK, Di Giovine FS, McDowell TL, Wilson AG, et al. Novel genetic association between ulcerative colitis and the antiinflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106: 637-42.
21. 2 shows stable interindividual differences. Scand J Immunol 1988; 27: 487-91.
22. Endres S, Cannon JG, Ghorbani R, Dempsey RA, Sisson SD, Lonnemann G, et al. In vitro production of IL 1β, IL 1α, TNF and IL-2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol 1989; 19: 2327-33.
23. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99: 303-10.
24. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
25. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, et al. Primer-directed enzymatic amplification of DNA with thermostable DNA polymerase. Science 1988; 239: 487-91.
26. Tountas NA, Yang H, Coulter DL, Rotter JI, Cominelli F. Increased carriage of allele 2 of IL-1 receptor antagonist (IL-1ra) in Jewish populations: the strongest known genetic association in ulcerative colitis [abstract]. Gastroenterology 1996; 110 (suppl): A1029.
27. Garcia-Paredes J, Bioque G, Crusius JBA, García-González A, López-Nava M, Diaz-Rubio M, et al. The interleukin-1 receptor antagonist gene polymorphism in Spanish IBD patients [abstract]. Gastroenterology 1996; 110 (suppl): A914.
28. Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein JS, et al. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993; 104: 749-58.
29. Nishiyama T, Mitsuyama K, Toyonaga A, Sasaki E, Tanikawa K. Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease. Digestion 1994; 55: 368-73.
30. Hyams JS, Fitzgerald JE, Wyzga N, Treem WR, Justinich CJ, Kreutzer DL. Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease. Dig Dis Sci 1994; 39: 1893-9.
31. Nakamura M, Saito H, Kasanuki J, Tamura Y, Yoshida S. Cytokine production in patients with inflammatory bowel disease. Gut 1992; 33: 933-7.
32. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992; 103: 1587-95.
33. Ferretti M, Casini RV, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994; 94: 449-53.
34. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992; 103: 65-71.
35. Thompson RC, Dripps DJ, Eisenberg SP. Interleukin-1 receptor antagonist (IL-1ra) as a probe and as a treatment for IL-1 mediated disease. Int J Immunopharmacol 1992; 14: 475-80.
36. Andus T, Vogl D, Aschenbrenner M, Köllinger M, Schölmerich M, Gross V. IL-1RA genotype 2 is associated with reduced IL-1RA in colonic mucosa [abstract]. Gastroenterology 1996; 110 (suppl): A855.